Trials / Completed
CompletedNCT04318704
Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
An Open Label Study of the Efficacy, Safety and Tolerability of NP-120 on Idiopathic Pulmonary Fibrosis and Its Associated Cough
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Algernon Pharmaceuticals · Industry
- Sex
- All
- Age
- 85 Years
- Healthy volunteers
- Not accepted
Summary
NP-120 (Ifenprodil) has been shown to mediate anti-inflammatory responses and reduce pulmonary fibrosis in a murine model of Idiopathic Pulmonary Fibrosis (IPF). In addition, NP-120 significantly reduced both cough frequency and onset in a guinea pig tussive model. The purpose of this proof-of-concept trial is to determine the efficacy of NP-120 in the treatment of IPF and its associated cough.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ifenprodil | Ifenprodil 20 mg TID |
Timeline
- Start date
- 2020-07-29
- Primary completion
- 2022-05-10
- Completion
- 2022-05-10
- First posted
- 2020-03-24
- Last updated
- 2022-07-19
Locations
6 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT04318704. Inclusion in this directory is not an endorsement.